IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	LEAKE, et al.	Examiner:	BOWMAN, Amy Hudson
Serial No.:	10/551350	Group Art Unit:	1635
Filed:	10/19/2006	Docket No.:	40590.0015USWO
Title:	MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE		

This paper is being electronically transmitted via EFS-Web to the U.S. Patent and Trademark Office.

1st SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2)(ii), a copy of each document or other information listed on the enclosed Form 1449 is provided, other than U.S. patent publications.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art."

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Date: August 26, 2009

23552 PATENT TRADEMARK OFFIC Respectfully submitted,

Steven N. Hird, Reg. No. 51,112 MERCHANT & GOULD P.C.

P.O. Box 2903 Minneapolis, Minnesota 55402-0903 303.357.1667